Ampulla of vater adenocarcinoma
diseaseOn this page
Also known as adenocarcinoma of ampulla of Vaterampullary adenocarcinomahepatopancreatic ampulla adenocarcinomainvasive adenocarcinoma of the ampullary region
Summary
Ampulla of vater adenocarcinoma (MONDO:0002670) is a disease and 11 clinical trials. Top therapeutic interventions include bevacizumab and adh-1. A subtype of extrahepatic bile duct adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 11
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ampulla of vater adenocarcinoma |
| Mondo ID | MONDO:0002670 |
| EFO | EFO:0008490 |
| DOID | DOID:3502 |
| ICD-11 | 1601321941 |
| NCIT | C6650 |
| UMLS | C1332243 |
| MedGen | 231054 |
| GARD | 0023208 |
| Anatomy (UBERON) | UBERON:0004913 |
| Is cancer (heuristic) | no |
Also known as: adenocarcinoma of ampulla of Vater · ampulla of Vater adenocarcinoma · ampullary adenocarcinoma · hepatopancreatic ampulla adenocarcinoma · invasive adenocarcinoma of the ampullary region
Data availability: 10 cell lines.
Disease family
An umbrella term covering 4 Mondo subtypes.
Classification path: human disease › disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › biliary tract cancer › bile duct cancer › bile duct carcinoma › extrahepatic bile duct carcinoma › extrahepatic bile duct adenocarcinoma › ampulla of vater adenocarcinoma
Related subtypes (6): extrahepatic bile duct signet ring cell carcinoma, extrahepatic bile duct mucinous adenocarcinoma, extrahepatic bile duct small cell adenocarcinoma, papillary extrahepatic bile duct adenocarcinoma, extrahepatic bile duct clear cell adenocarcinoma, adenocarcinoma of gallbladder and extrahepatic biliary tract
Subtypes (4): ampullary signet ring cell adenocarcinoma, ampulla of vater mucinous adenocarcinoma, ampulla of vater clear cell adenocarcinoma, periampullary adenocarcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 11.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 5 |
| PHASE2 | 2 |
| PHASE4 | 1 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07262957 | PHASE4 | RECRUITING | Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA) |
| NCT06813976 | PHASE3 | RECRUITING | PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma |
| NCT05116072 | PHASE1/PHASE2 | RECRUITING | Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula |
| NCT07282912 | PHASE2 | RECRUITING | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels |
| NCT01208103 | PHASE2 | COMPLETED | Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma |
| NCT01825603 | PHASE1 | COMPLETED | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer |
| NCT02757859 | Not specified | ACTIVE_NOT_RECRUITING | WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer |
| NCT06068023 | Not specified | RECRUITING | The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. |
| NCT07560540 | Not specified | RECRUITING | Nutritional Intervention Implication in Enhanced Recovery After Surgery for Whipple Procedure |
| NCT03800212 | Not specified | UNKNOWN | Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma |
| NCT04400357 | Not specified | COMPLETED | Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 1 |
| ADH-1 | 1 | 1 |
Related Atlas pages
- Drugs: Bevacizumab